Home
Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info
The page you're viewing now, as well as 140,000+ other pages from Natural News, have all been CENSORED by Google due to a "human decision" to silence this entire website. Google's abuse of monopoly power to suppress human knowledge must be stopped. SIGN THIS WHITE HOUSE PETITION NOW and demand an investigation into Google's anti-trust violations and censorship of speech.

Google refuses to provide any evidence to justify blacklisting Natural News

How Google LIED | PROOF: HuffPo, BuzzFeed, Forbes, CNN violations ignored by Google

Health news

Chinese Moss Extract Tested as Alzheimer's Drug (press release)

Monday, August 07, 2006 by: NewsTarget
Tags: health news, Natural News, nutrition

Most Viewed Articles
Popular on Facebook
http://www.naturalnews.com/019886_Alzheimers_Chinese_drug.html
Delicious
diaspora
Print
Email
Share
Can a compound derived from the Chinese club moss Huperzia serrata improve brain function in Alzheimer's patients?

That's a question U.S. researchers hope to answer as they recruit participants for a new clinical trial on the compound, called huperzine A, from 28 sites across the country.

The Phase II clinical trial to determine the safety and efficacy of huperzine A will enroll about 150 patients, age 55 and older, with mild to moderate Alzheimer's disease. Huperzine A is a naturally occurring cholinesterase inhibitor that's commonly used in China to treat Alzheimer's.

Chinese studies have suggested it is well tolerated and effective. However, there have been no controlled clinical trials of huperzine A outside of China.

"Based on studies in China, huperzine A may be more effective and better tolerated than currently prescribed drugs for Alzheimer's disease. In addition, laboratory studies suggest that huperzine A may have unique effects that could slow down the progression of the disease," Dr. Paul Aisen, leader of the new study and professor of neurology at Georgetown University Medical Center's Memory Disorders Program, said in a prepared statement.

"This trial is essential to better understand the promise of huperzine A," Aisen said. "Though it is a rigorous placebo-controlled trial, all participants do receive the active medication. The first portion of the trial, lasting 16 weeks, includes a placebo arm, but all participants have the opportunity to take active huperzine A for at least eight months.

The study, directed by Georgetown University researchers, is funded by the U.S. National Institutes of Health and Neuro-Hitech Pharmaceuticals Inc.

Join the Health Ranger's FREE email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Your privacy is protected. Unsubscribe at any time. | Learn more...
comments powered by Disqus